表紙
市場調査レポート

中国のOTC医薬品市場の分析

Research Report on China's OTC Drug Market, 2013-2017

発行 China Research and Intelligence 商品コード 273671
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
中国のOTC医薬品市場の分析 Research Report on China's OTC Drug Market, 2013-2017
出版日: 2013年05月30日 ページ情報: 英文 30 Pages
概要

先進国と比べると、中国のOTC医薬品市場には遅いスタートと急速な成長、巨大な潜在的市場といった特徴があります。中国のOCT医薬品産業は2000〜2012年に年平均(CAGR)18%以上の速度で成長し、2012年には1700億人民元以上の規模となりました。急速な高齢化や都市化、政府の支援、市民の健康意識の高まりなどが主な成長促進要因となっています。今後も、処方薬からの切り替えや農村部の所得向上に伴い、OTC医薬品市場は年率15%で成長し、世界最大の市場となると予想されます。

当レポートでは、中国におけるOTC医薬品(一般用医薬品、大衆薬)の市場について分析し、全体的な産業構造や、市場競争の現状、主要メーカーのプロファイル、今後の市場動向などを調査・推計して、その結果を概略以下の構成でお届けします。

第1章 OTC医薬品の基本的概念

  • OTC医薬品の定義
  • OTC医薬品と処方薬の違い
  • OTC医薬品産業の発展過程
  • OTC医薬品の特徴
    • 柔軟性の高さ
    • OTC医薬品産業の技術的特徴
    • ブランド薬の消費に関する選好

第2章 中国OTC医薬品産業の分析

  • OTC医薬品の種類:概要
  • 市場規模
  • OTC医薬品メーカーの概要

第3章 中国のOTC医薬品市場の競争状況

  • 業界の競争状況
  • 下流工程産業
  • 潜在的な参入企業

第4章 主要OTC医薬品メーカーの分析

  • Harbin Pharmaceutical Group Co., Ltd
  • Huarun Sanjiu Medical & Pharmaceutical Co., Ltd
  • Renhe (Group) Development Co., Ltd
  • Xi'an-Janssen Pharmaceutical Co., Ltd
  • Wyeth Pharmaceutical Co., Ltd
  • Yangtze River Pharmaceutical Group
  • Tianjin SK&F Pharmaceutical Co., Ltd
  • Yunnan Baiyao Group Co., Ltd
  • Jiangzhong Pharmaceutical Co., Ltd
  • Zhejiang Conba Pharmaceutical Co., Ltd

第5章 中国のOTC医薬品産業の発展予測

  • 「種類の転換」(Conversion of Varieties)に伴う、OTC医薬品産業の成長促進
  • 慢性病の発症率上昇による、市場需要の拡大
  • 中国市民の健康意識の上昇による、OTC医薬品市場の発展
  • 都市化の加速化に伴う、OTC医薬品の市場規模の拡大
  • OTC医薬品の市場規模の予測(今後5年間分)
  • 今後の投資・開発に関する提言

図表一覧

目次

Since OTC drugs are mainly used by consumers without a physician's prescription in treating certain common ailments which are easy for self-diagnosis and self-treatment, the structure of their terminal market is relatively stable. The Top 4 categories of OTC drugs in Chinese market include cough and cold medications and anti-allergic agents, recuperated drugs, vitamins & minerals and tonic drugs as well as febrifuges and painkillers. The features of OTC drugs determine that this industry has low technical barriers and low entrant requirements. As a result, in China, there are many OTC drug manufacturing enterprises, most of which are small and medium enterprises with insufficient capital and non-advanced techniques. Besides, the homogeneity of the products is serious so that it is difficult to establish brand images.

Compared with that of countries with advanced medicine levels, China OTC drug industry is featured by late start, fast growth and huge potential.According to CRI's research, with a CAGR of over 18% during the period from 2000 to 2012, the market scale of China OTC drug industry exceeded CNY 170 billion in 2012.

With the increase in chronic disease incidence rate and residents' healthcare consciousness, consumers purchasing OTC drugs will become a universal phenomenon and its market demand will be continuously expanded. Meanwhile, in order to ease the stress exerted by the shortage of expenditures on healthcare, Chinese government is supposed to put forward new policies to support OTC drug market, to accelerate OTC drug transition, to increase OTC drug market share and to help China OTC drug industry to enter into a stable growing stage.

The OTC drug industry is featured by obvious brand consumption. Therefore, famous brand products occupy the mainstream market, while those less famous brands is difficult to sell. They can only make up market vacancy by virtue of uniqueness or occupy market by regional advantages. With the standardizing development of domestic OTC drug market and the increase in residents' healthcare consciousness, the competition focus will be inevitably conversed from quality and price competition to brand and service competition. The increase in industry brand barrier makes it difficult for generic drug enterprises to build up brand images. There is an obvious trend on industry differentiation. Therefore, brand enterprises will become the biggest beneficiary in expanded OTC market.

With the development of China OTC drug industry, Chinese medicine retail terminal has rapidly risen to the major sales channel of OTC drugs. With drugstores catenation, the bargaining ability of downstream industries has been improved and brand co-operation has become the inevitable choice for the market. Famous brands give great support to the terminal market, while those less famous brands, jointed with the famous brands, make great efforts to coordinate the profit distribution in the entire industry chain so as to leave enough profit-earning opportunities for the retail terminals.

It is predicted by CRI that the switches between Rx and OTC products, the increasing trend of aging population in China and the increase in rural residents' incomes will become the major driving forces for the development of China OTC drug market. It is also estimated by CRI that the CAGR of China OTC drug market scale will maintain above 15%, which indicates that China will become the key OTC drug market in the world.

Through this report, the readers can acquire the following information:

  • Current Development Status of China OTC Drug Industry
  • Development Environment of China OTC Drug Industry
  • Market Competition Status of China OTC Drug Industry
  • Key OTC Drug Manufacturing Enterprises in China
  • Development Prospect and Potential Investment Opportunity in China OTC Drug Market

The Following Enterprises and People are proposed to purchase this report:

  • Pharmaceutical Enterprises
  • Medicine Trade Enterprises/Hospitals
  • Investors, Research Institutes and Government Departments Concerned about OTC Drug Market

Table of Contents

1. Basic Concept of OTC Drugs

  • 1.1. Definition of OTC Drugs
  • 1.2. Differences Between OTC Drugs and Rx Drugs
  • 1.3. Development Progress of the OTC Drug Industry
  • 1.4. Features of OTC Drugs
    • 1.4.1. High Flexibility
    • 1.4.2. Technical Features of the OTC Drug Industry
    • 1.4.3. Preference for Brand Consumption

2. Analyses on the OTC Drug Industry in China, 2013-2017

  • 2.1. Overview on Varieties of OTC Drugs
  • 2.2. Market Scale
  • 2.3. Overview on OTC Drug Manufacturing Enterprises

3. Market Competition Status of China OTC Drug Industry, 2008-2012

  • 3.1. Industry Competition Status
  • 3.2. Downstream Industry
  • 3.3. Potential Entrants

4. Analyses on Key OTC Drug Manufacturing Enterprises in China

  • 4.1. Harbin Pharmaceutical Group Co., Ltd
  • 4.2. Huarun Sanjiu Medical & Pharmaceutical Co., Ltd
  • 4.3. Renhe (Group) Development Co., Ltd
  • 4.4. Xi'an-Janssen Pharmaceutical Co., Ltd
  • 4.5. Wyeth Pharmaceutical Co., Ltd
  • 4.6. Yangtze River Pharmaceutical Group
  • 4.7. Tianjin SK&F Pharmaceutical Co., Ltd
  • 4.8. Yunnan Baiyao Group Co., Ltd
  • 4.9. Jiangzhong Pharmaceutical Co., Ltd
  • 4.10. Zhejiang Conba Pharmaceutical Co., Ltd

5. Forecasts on the Development of China OTC Drug Industry, 2013-2017

  • 5.1. Conversion of Varieties Promote the Growth of the OTC Drug Industry
  • 5.2. Increasing Incidence Rate of Chronic Diseases Boosts the Market Demand
  • 5.3. Increasing Healthcare Consciousness of Chinese Residents Promotes OTC Drug Market Development
  • 5.4. Accelerating Urbanization Process Enlarges OTC Drug Market Scale
  • 5.5. Forecast on OTC Drug Market Scale, 2013-2017
  • 5.6. Recommendations on the Investment and Development

Selected Charts

  • Chart Differences Between Rx Drug and OTC Drug
  • Chart Category Management of Drugs in Some Countries
  • Chart Advertising Restrictions on Drugs in Some Countries
  • Chart Expansion Status of OTC Drug Catalog in China
  • Chart Market Scale of OTC Drugs in China, 2008-2012
  • Chart Proportion of OTC Drug Sales in the Total Drug Sales in China, 2008-2012
  • Chart Ranking of China OTC Drug Manufacturing Enterprises in 2012
  • Chart Chain Drugstores with Private Brands or Higher Proportion of High Gross Profit Products
  • Chart Chain Drugstores with Private Brands or Lower Proportion of High Gross Profit Products
  • Chart Newly-added OTC Drugs in China After Restarting Evaluation Work
  • Chart Number of Chinese Aged People (65 years old and above)
  • Chart Healthcare Expenditure Per Capita of Urban and Rural Residents in China, 2001-2011
  • Chart Population Urbanization Rate in China, 2001-2012
  • Chart Forecast on China OTC Drug Market Scale, 2013-2017
Back to Top